AbbVie Inc. Share Price

Equities

ABBV

US00287Y1091

Pharmaceuticals

Market Closed - Nyse 21:00:02 22/04/2024 BST 5-day change 1st Jan Change
167.9 USD +0.89% Intraday chart for AbbVie Inc. +3.85% +8.34%
Sales 2024 * 54.57B 4,421B Sales 2025 * 57.78B 4,681B Capitalization 295B 23,871B
Net income 2024 * 9.08B 736B Net income 2025 * 11.09B 899B EV / Sales 2024 * 6.38 x
Net Debt 2024 * 53.67B 4,348B Net Debt 2025 * 45.01B 3,647B EV / Sales 2025 * 5.88 x
P/E ratio 2024 *
30 x
P/E ratio 2025 *
24.7 x
Employees 50,000
Yield 2024 *
3.76%
Yield 2025 *
3.92%
Free-Float 96.75%
More Fundamentals * Assessed data
Dynamic Chart
1 day+1.16%
1 week+4.26%
Current month-7.44%
1 month-5.54%
3 months+1.92%
6 months+16.47%
Current year+8.77%
More quotes
1 week
162.08
Extreme 162.0772
168.95
1 month
160.00
Extreme 160
182.30
Current year
154.77
Extreme 154.7704
182.89
1 year
130.96
Extreme 130.9601
182.89
3 years
105.56
Extreme 105.56
182.89
5 years
62.55
Extreme 62.55
182.89
10 years
45.45
Extreme 45.45
182.89
More quotes
Managers TitleAgeSince
Chief Executive Officer 70 31/12/12
Director of Finance/CFO 57 31/12/12
President 53 31/12/11
Members of the board TitleAgeSince
Director/Board Member 63 31/12/12
Director/Board Member 66 31/12/12
Director/Board Member 70 31/12/12
More insiders
Date Price Change Volume
22/04/24 167.9 +0.89% 5 549 167
19/04/24 166.4 +1.06% 5,532,492
18/04/24 164.7 +0.25% 4,480,224
17/04/24 164.2 +1.05% 4,792,382
16/04/24 162.5 +0.54% 4,881,516

Delayed Quote Nyse, April 22, 2024 at 05:15 pm

More quotes
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
166.4 USD
Average target price
184.1 USD
Spread / Average Target
+10.66%
Consensus